Giovanni Caforio, Bristol Myers Squibb CEO (via AP)
Will they or won't they? The countdown on Bristol Myers' $6B CVR winds down to a hard deadline at the FDA
Tick. Tick. Tick.
A small but intensely devoted group of investors holding on to the CVRs from the Celgene buyout are spending a good part …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
